إعلان
إعلان
SABS
SAB Biotherapeutics, Inc. Common Stock
3.67
USDبرعاية
-0.19
-4.92%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
3.81
+0.14
+3.81%
تقارير أرباح SABS
النسبة الإيجابية المفاجئة
SABS تفوق 11 من 17 آخر التقديرات.
65%
التقرير التالي
بيانات التقرير القادم
٣٠ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.18
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/+20.00%
التغير الضمني من Q4 24 (Revenue/ EPS)
-100.00%
/-85.25%
SAB Biotherapeutics, Inc. Common Stock earnings per share and revenue
On ١٤ نوفمبر ٢٠٢٥, SABS reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.51 USD, resulting in a 70.94% surprise. Revenue reached --, compared to an expected 102.00 ألف, with a -100.00% difference. The market reacted with a +4.52% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 المحللين forecast an EPS of -0.18 USD, with revenue projected to reach -- USD, implying an زيادة of 20.00% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were SAB Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, SAB Biotherapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 70.94%, and revenue of $0.00, -100% below expectations.
How did the market react to SAB Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 4.52%, changed from $3.10 before the earnings release to $3.24 the day after.
When is SAB Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٣٠ مارس ٢٠٢٦.
What are the forecasts for SAB Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 9
المحللين, SAB Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان